Hematopoietic stem cells transplantation (HSCT) market by Application, Type and Geography - Forecast and Analysis 2023-2027

Hematopoietic Stem Cells Transplantation (HSCT) Market Forecast 2023-2027

The global hematopoietic stem cells transplantation (HSCT) market size is estimated to grow by USD 2.38 billion between 2022 and 2027 and the size of the market is expected to accelerate at a CAGR of 6.5%. Factors influencing market growth include the advancement of technology, rising demand for customized medicine, and decreased morbidity and mortality rates. The improved treatment options, HLA typing, and supportive care given to patients prior to or after the transplant help them fight infectious diseases and that is why hematopoietic stem cell transplantation has become a preferable option. Owing to the increasing emergence of regenerative therapies across the world, this market will significantly grow during the forecast period. It is an oligopoly market that is mainly dominated by key vendors such as AllCells, Lonza, Merck, and Sanofi, followed by other prominent vendors such as STEMCELL Technologies and Mesoblast. The market is witnessing strong research and development in the field of stem cells, which is expected to help some new companies enter the market.

It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download the FREE Report Sample

Market Segmentation

Technavio has segmented the market on the basis of Application, Type, and Geography. The application segment is divided into bone marrow transplant, peripheral blood stem cell transplant, and cord blood transplant, the type segment is fragmented into autologous HSCT and allogeneic HSCT followed by geography which includes key regions such as North America, Europe, Asia, and Rest of World.

Market Segmentation by Application, Type, and Geography

The market plays a crucial role in treating various hematological disorders such as leukemia and lymphoma, which are significant health concerns globally. Organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) provide guidelines and support for managing these conditions. Autologous transplantation and allogeneic transplantation, including bone marrow transplant and cord blood transplant, are common procedures in this market. Healthcare providers like the Leukemia & Lymphoma Society (LLS) contribute significantly to research, clinical trials, and therapies for lymphoproliferative disorders. The rising prevalence of cancer and its status as a leading cause of death emphasizes the importance of advancements in stem cell transplants and therapeutic cells, driving inorganic growth strategies and addressing the public health emergency posed by these conditions.

Application Analysis

The bone marrow transplant segment is estimated to witness significant growth during the forecast period.  A bone marrow transplant is a treatment that replaces bone marrow that is not producing enough healthy blood cells or is dysfunctional with healthy blood-forming stem cells. Doctors and medical practitioners recommend bone marrow transplants to patients suffering from several malignant and noncancerous disorders, including acute leukemia, adrenoleukodystrophy, chronic leukemia, aplastic anemia, bone marrow failure syndromes, and others.

Get a glance at the market contribution of various segments Request a PDF Sample

The bone marrow transplant segment was valued at USD 2.61 billion in 2017 and continues to grow during the forecast period. Bone marrow transplant also improves the prospects of cure and survival for patients with such disorders, resulting in a rising demand for bone marrow transplants among patients. This, in turn, will fuel the global hematopoietic stem cell transplantation (HSCT) market's growth throughout the forecast period.

Type Analysis

The type segment is divided into two parts: autologous HSCT and allogeneic HSCT. The major advantage of an autologous transplant is the body recognizes its cells, and hence, does not reject the transplant. This also indicates lesser chances of GvHD. The autologous HSCT segment of the global market currently dominates the global market, with the highest market share of 59.00% in 2021. Moreover, autologous transplant involves cryopreservation of the stem cells, which allows the administration of high doses of chemotherapy and radiotherapy to be risk-free. Further, an autologous transplant ensures rapid immune recovery of the patients, which would ultimately drive market growth during the forecast period.

To learn more about segments download the sample reports!

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request PDF Sample now!

In 2022, the US was the largest revenue contributor to the HSCT market in the region, attributed to the increasing awareness about stem cell therapy in the country and the availability of advanced healthcare infrastructure. This ensures the continuous delivery of therapies to patients undergoing treatment. Hence, the market in the US is expected to grow steadily during the forecast period.

Unlike the traditional therapeutic market, there are a number of policies and regulation-related considerations pertaining to the use of stem cell therapies. However, despite stringent regulations laid by regulatory authorities in the region, many factors, such as the high prevalence of bone marrow diseases and several types of blood carcinomas, are propelling the market growth in North America. Furthermore, healthcare is financed through a mix of financing arrangements, including government spending and compulsory health insurance, as well as voluntary health insurance and private funds such as households' out-of-pocket payments, NGOs, and private corporations (together termed as voluntary). All these factors are expected to drive the growth of the market in the US and, subsequently, in North America.

Key Players in Market 

There is high competition in the Market. Among several market players, the organization AllCells Corp stands out among the competitors due to technological innovation and the on-point marketing strategy. 

AllCells Corp- To make an impact in the hematopoietic stem cells industry, the company provides a wide range of human hematopoietic cells and molecular products such as whole blood, leukoplakia, mobilized leukoplakia, bone marrow, and cord blood.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:

• Athersys Inc.
• Beike Biotechnology Co. Ltd.
• Bluebird bio Inc.
• Cellular Biomedicine Group Inc.
• FUJIFILM Corp.
• Gamida Cell Ltd.
• Lineage Cell Therapeutics Inc.
• Lonza Group Ltd.
• MEDIPOST Co. Ltd.
• Merck and Co. Inc.
• Mesoblast Ltd.
• Pluristem Therapeutics Inc.
• Sanofi SA
• Sartorius CellGenix GmbH
• Taiga Biotechnologies Inc.
• Takeda Pharmaceutical Co. Ltd.
• Talaris Therapeutics Inc.
• ThermoGenesis Holdings Inc.
• AllCells Corp.

Technavio’s report consists of a holistic analysis of the key development analysis,  development stage,  pipeline analysis,  FDA approval, market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge. 

Market Dynamics and Customer Landscape

The market is driven by factors such as increasing cases of leukemia and lymphoma, prompting organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to emphasize research and treatment protocols. Advancements in autologous transplantation and allogeneic transplantation, along with innovative therapies from companies like Magenta Biosciences and Gamida Cell, are key trends. However, challenges like high healthcare expenditure, managing graft-versus-host disease (GVHD), and addressing the public health emergency of hematological disorders remain significant hurdles in the HSCT market. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Driver

Recent years have witnessed a rise in the adoption of hematopoietic stem cells transplantation (HSCT) due to the development of safer procedures and improved success rates resulting from technological advancements. This trend is expected to continue during the forecast period, with the global HSCT market being driven by advancements in technology, particularly the development of better and more sophisticated instruments. For example, Ranfac has introduced its patented technology, Marrow Cellution, to address the challenges associated with conventional transplant syringes.

Moreover, the use of traditional needles has often led to contamination of peripheral blood, resulting in poor cellular yield. This has necessitated the adoption of measures to meet the desired cellular demands for treating various diseases. Therefore, the Marrow Cellution technology, which enables high-quality stem and progenitor cells to be harvested within a narrow space with limited peripheral blood contamination, is expected to fuel the market growth during the forecast period

Significant Market Trend

Growing demand for personalized medicine is a notable trend in the market. The concept of personalized medicine involves tailoring treatments to the specific needs, characteristics, and preferences of individual patients. To this end, research organizations are exploring various ways to develop personalized treatments using mesenchymal stem cells due to their numerous benefits. These benefits include a lower risk of immune rejection, no need for embryonic stem cells, reduced dependence on anti-rejection drugs, lower risk of graft rejection, and a decreased chance of developing GvHD.

While immunosuppressive therapy is the mainstay of treatment for hematological malignancies and solid tumors, its side effects often outweigh its therapeutic benefits. Mesenchymal stem cells (MSC), which are located in the vascular region of the bone marrow, provide cellular support to the HSC niche and possess immunosuppressive properties that are beneficial for HSCT and the treatment of inflammatory and autoimmune diseases. As a result, the use of MSC during HSCT has led to improved engraftment rates of hematopoietic stem cells by reducing the incidence of GvHD, which is expected to contribute to market growth during the forecast period.

Major Market Challenge

Increased risk of complications post-HSCT is a major challenge in the market. The field of transplant technology and supportive care practices has seen significant advancements, resulting in improved survival rates among patients following transplantation. However, despite these developments, individuals who have undergone hematopoietic stem cell transplantation (HSCT) remain at risk of developing long-term complications, including endocrinopathy, cardiopulmonary issues, musculoskeletal disorders, and subsequent malignancies.

Moreover, these complications have a direct impact on the mortality and morbidity rates of HSCT patients. As a result, the increased morbidity experienced by HSCT patients has led to a growing demand for alternative treatment regimens, which is hindering market growth during the forecast period.

To learn more about drivers, trends, and challenges  download the sample reports!

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides a market growth analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Type Outlook 
  • Autologous HSCT
  • Allogeneic HSCT

• Application Outlook
  • Bone marrow transplant
  • Peripheral blood stem cell transplant
  • Cord blood transplant

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview

The market is a critical aspect of modern healthcare, addressing complex conditions like lymphoma, leukemia, and graft-versus-host disease (GVHD). Organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) play pivotal roles in research and advocacy. Companies such as Magenta Biosciences and Priothera are driving innovations in stem cell-based medicines and immune cloaking technologies. The market witnesses substantial investments in therapeutic and diagnostic devices for transplantation procedures like autologous and allogeneic transplantation. However, challenges like reduction in bed capacity and healthcare expenditure persist, emphasizing the need for continual advancements and collaborations in this critical area of healthcare.

Moreover, the market is a vital component of the healthcare industry, particularly in addressing complex conditions such as leukemia, lymphoma, and hematological disorders. Organizations like the World Cancer Research Fund and the Leukemia & Lymphoma Society (LLS) play crucial roles in funding research and supporting patients diagnosed with common cancers. Clinical trials and innovative treatments like autologous and allogeneic transplant therapy for bone marrow stem cell transplant are conducted at renowned centers like QUINT Bone Marrow Transplant Center. Companies like Clade Therapeutics focus on induced pluripotent stem cells (iPSCs) and therapeutic cells for effective treatment. However, challenges such as reduction in bed capacity and demand for drugs highlight the need for continuous advancements and collaborations in this field. The American College of Surgeons (ACS) guides surgical interventions, including bone marrow transplant (BMT), peripheral blood stem cells transplant (PBSCT), and cord blood transplant (CBT), further underlining the significance of HSCT in combating life-threatening conditions.

Furthermore, the market is a critical aspect of healthcare, particularly in addressing hematological disorders like acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). Autologous transplantation and stem cell transplants are key therapies for these conditions, helping combat lymphoproliferative disorders and reduce the prevalence of cancer, which is a leading cause of death worldwide. However, challenges such as acute graft-versus-host disease (GVHD), reduction in bed and operating room capacity, and production and demand of drugs present obstacles in effectively managing these diseases. Strategic initiatives like inorganic growth strategies are being employed to address the public health emergency posed by these disorders and ensure access to life-saving treatments for patients.

Market Scope
Report Coverage	Details
Page number	159
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.5%
Market growth 2023-2027	USD 2.38 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	5.89
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 40%
Key countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., FUJIFILM Corp., Gamida Cell Ltd., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck and Co. Inc., Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics Inc., ThermoGenesis Holdings Inc., and AllCells Corp.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the market in focus on the parent market
• Detailed market research and growth analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Vendor landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on vendor position and classification
• Accurate predictions about upcoming market trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and the Rest of World (ROW)
• A thorough market research report analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market growth and forecasting analysis of factors that will challenge the growth of hematopoietic stem cells transplantation (HSCT) market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch